Executive Officer decisions and Committee to Evaluate Drugs recommendations
Find information on drug funding decisions based on Executive Officer decisions and Committee to Evaluate Drugs (CED) recommendations. This information is intended for medical professionals and drug manufacturers.
Overview
The information below is intended only to provide the recommendations from the Committee to Evaluate Drugs (CED) and decisions by the Executive Officer regarding:
- the listing of products on the Formulary
- funding of cancer drugs through the New Drug Funding Program (NDFP)
- funding through the Exceptional Access Program (EAP)
- funding through the Special Drugs Program (SDP)
The CED reviews select drugs for public funding in Ontario. The Executive Officer (EO), Ontario Public Drug Programs, seeks the committee’s advice in making final funding decisions. Please note that the specific drugs (for example, specific drug identification numbers [DINs]) reviewed by the Canadian Agency for Drugs and Technologies of Health (CADTH) Common Drug Review process are not subsequently assessed by this committee .